Holen Sie sich die Stockscreener-App
98.08
0.06%
-0.0757
Schlusskurs vom Vortag:
$98.00
Offen:
$99.06
24-Stunden-Volumen:
393.49K
Relative Volume:
0.76
Marktkapitalisierung:
$7.71B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-224.29M
KGV:
-25.15
EPS:
-3.9
Netto-Cashflow:
$-185.06M
1W Leistung:
-1.48%
1M Leistung:
-2.86%
6M Leistung:
+21.71%
1J Leistung:
+31.49%
1-Tages-Spanne:
$96.06
$101.82
1-Wochen-Bereich:
$96.06
$103.85
52-Wochen-Spanne:
$55.53
$113.02
Nuvalent Inc Stock (NUVL) Company Profile
Firmenname
Nuvalent Inc
Sektor
Branche
Telefon
508-446-2272
Adresse
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
Compare NUVL vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NUVL
Nuvalent Inc
|
98.11 | 7.70B | 0 | -224.29M | -185.06M | -3.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.68 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
747.04 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
704.66 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.76 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.33 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-11-12 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-10-16 | Fortgesetzt | Stifel | Buy |
| 2025-10-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-09-04 | Fortgesetzt | Guggenheim | Buy |
| 2025-09-03 | Eingeleitet | Raymond James | Outperform |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2025-03-14 | Hochstufung | UBS | Neutral → Buy |
| 2024-12-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-10-24 | Eingeleitet | UBS | Neutral |
| 2024-08-29 | Eingeleitet | Barclays | Overweight |
| 2024-04-17 | Eingeleitet | Jefferies | Buy |
| 2024-04-01 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-02-28 | Fortgesetzt | Guggenheim | Buy |
| 2024-02-23 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-09-27 | Eingeleitet | Stifel | Buy |
| 2023-08-08 | Eingeleitet | SVB Securities | Market Perform |
| 2023-07-24 | Eingeleitet | Guggenheim | Buy |
| 2023-01-18 | Eingeleitet | Wedbush | Outperform |
| 2022-06-24 | Eingeleitet | BMO Capital Markets | Outperform |
Alle ansehen
Nuvalent Inc Aktie (NUVL) Neueste Nachrichten
Is It Time To Reassess Nuvalent (NUVL) After Recent Trial And Pipeline Updates - simplywall.st
Assessing Nuvalent (NUVL) Valuation After Widening Losses And A New US$458.4m Shelf Registration - Yahoo Finance
25,160 Shares in Nuvalent, Inc. $NUVL Acquired by Jefferies Financial Group Inc. - MarketBeat
(NUVL) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
American Century Companies Inc. Sells 11,767 Shares of Nuvalent, Inc. $NUVL - MarketBeat
Growth Value: Should I set a stop loss on Nuvalent IncMarket Risk Summary & Real-Time Market Sentiment Reports - baoquankhu1.vn
Citigroup Inc. Has $3.04 Million Holdings in Nuvalent, Inc. $NUVL - MarketBeat
Aug Sentiment: Will Nuvalent Inc benefit from green energy policiesWeekly Trading Summary & Daily Volume Surge Trade Alerts - baoquankhu1.vn
HC Wainwright Brokers Lift Earnings Estimates for Nuvalent - MarketBeat
Analysts Offer Insights on Healthcare Companies: Quantum-Si (QSI), Moderna (MRNA) and Nuvalent (NUVL) - The Globe and Mail
NUVL: Regulatory filings and commercial launches for ALK and ROS1 NSCLC therapies are on track for 2024 - TradingView
HC Wainwright Brokers Reduce Earnings Estimates for Nuvalent - MarketBeat
NUVLForm S-8Securities to be offered to employees in employee benefit plans - mx.advfn.com
Nuvalent Outlines Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2025 Financial Results - mx.advfn.com
TD Asset Management Inc Increases Position in Nuvalent, Inc. $NUVL - MarketBeat
NUVL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Nuvalent Insider Sold Shares Worth $566,788, According to a Recent SEC Filing - marketscreener.com
Nuvalent Executives Sell Shares Under Trading Plan - TradingView
Nuvalent (NUVL) CDO exercises options and sells 5,500 shares under 10b5-1 plan - Stock Titan
Nuvalent (NUVL) CLO sells 5,500 shares after option exercise - Stock Titan
Assessing Nuvalent (NUVL) Valuation After Recent Share Price Cooling And Strong Multi Year Returns - simplywall.st
Nuvalent, Inc. (NUVL) Stock Analysis: A Biotech With A Promising 40.78% Upside Potential - DirectorsTalk Interviews
UBS Adjusts Price Target on Nuvalent to $138 From $132, Maintains Buy Rating - marketscreener.com
Analysts Are Bullish on These Healthcare Stocks: Nuvalent (NUVL), Atai Beckley N.V. (ATAI) - The Globe and Mail
Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29% - AOL.com
Does Nuvalent (NUVL) Have the Potential to Rally 37.26% as Wall Street Analysts Expect? - Finviz
Does Nuvalent (NUVL) Have a Chance to Surge by 37.26% According to Wall Street Analysts? - Bitget
Nuvalent (NASDAQ:NUVL) Stock Price Expected to Rise, Cantor Fitzgerald Analyst Says - MarketBeat
Vanguard Group Inc. Raises Holdings in Nuvalent, Inc. $NUVL - MarketBeat
Decoding Nuvalent Inc (NUVL): A Strategic SWOT Insight - GuruFocus
Nuvalent reports Q4 loss, awaits FDA decision on lung cancer drug - Investing.com Australia
Nuvalent, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Nuvalent reports Q4 loss, awaits FDA decision on lung cancer drug By Investing.com - Investing.com South Africa
Nuvalent, Inc. SEC 10-K Report - TradingView
Nuvalent (NUVL) targets 2026 launches with ROS1 and ALK lung cancer drugs - Stock Titan
(NUVL) Risk Channels and Responsive Allocation - Stock Traders Daily
Nuvalent (NUVL) details 2025 results and key FDA milestones - Stock Titan
BRIEF-Nuvalent Q4 EPS USD -1.58 - TradingView
Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29% - The Motley Fool
Nuvalent, Inc. (NUVL) Stock Analysis: Exploring a 41.94% Potential Upside Amidst Strong Buy Ratings - DirectorsTalk Interviews
Biotech Fund Trims Nuvalent Stake After 29% Stock Surge - National Today
Nuvalent, Inc. (NASDAQ:NUVL) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Nuvalent, Inc. (NASDAQ:NUVL) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Is Nuvalent (NASDAQ:NUVL) Entering a Key Phase With Nasdaq Index Fund - Kalkine Media
Nuvalent (NUVL) Projected to Post Earnings on Thursday - MarketBeat
Trust linked to Nuvalent (NUVL) files Form 144 to sell 1,650 shares - Stock Titan
Bank Watch: Is Nuvalent Inc forming a bullish divergenceMarket Risk Analysis & Fast Gain Swing Alerts - baoquankhu1.vn
(NUVL) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Nuvalent Details FDA Timelines for ROS1, ALK Drugs as $1.4B Cash Fuels Global Launch Plans - MarketBeat
NUVL: Global launches of innovative ROS1 and ALK inhibitors drive growth and pipeline expansion - TradingView
Nuvalent honors women pioneers on Women in Science Day - Traders Union
Finanzdaten der Nuvalent Inc-Aktie (NUVL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Nuvalent Inc-Aktie (NUVL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Porter James Richard | President and CEO |
Mar 06 '26 |
Option Exercise |
27.85 |
30,000 |
835,500 |
354,879 |
| Porter James Richard | President and CEO |
Mar 06 '26 |
Sale |
98.99 |
30,000 |
2,969,550 |
324,879 |
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):